Back to News
Jun 1, 2026 12:50 PM

Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls

Moderna, Inc. (NASDAQ:MRNA) stock is trading lower on Monday.

The COVID-19 vaccine maker and Merck & Co Inc. (NYSE:MRK) reported five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) plus KEYTRUDA for high-risk stage III/IV melanoma after complete surgical resection.

• Moderna stock is under selling pressure. What’s driving MRNA stock lower?

Combination Continues To Show Durable Melanoma Benefits

After a median follow-up of 60.3 months, the combination continued to show durable benefits, reducing the risk of recurrence or death by 49% compared with KEYTRUDA alone, meeting the study’s primary endpoint of recurrence-free survival (RFS).

The combination also improved the key secondary endpoint of distant metastasis-free survival (DMFS), lowering the risk of distant metastasis or death by 59% versus KEYTRUDA alone.

Read ...